Propanc Biopharma Debt to Equity

Propanc Biopharma (PPCB) currently reports a debt-to-equity ratio of 0.05. That is above the Healthcare sector average of -8.5. Use the charts on this page to explore Propanc Biopharma's debt-to-equity ratio history and peer comparisons.

Propanc Biopharma's debt-to-equity ratio of 0.05 is higher than the Healthcare sector average of -8.5. That is roughly 100.6% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The debt-to-equity ratio is a valuation multiple that relates Propanc Biopharma's market price to a fundamental measure such as earnings, sales, or book value. At 0.05, PPCB can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current debt-to-equity ratio of 0.05, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -8.5. From there, open related valuation or income-statement pages for Propanc Biopharma, and consider following PPCB for alerts when major investors trade the stock.

Propanc Biopharma is classified in the Healthcare sector. On debt-to-equity ratio, it currently shows 0.05 versus a sector average near -8.5. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PPCB with unrelated industries.